Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
Pharmacotherapy
|
December 17, 1997
Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors
J L Lagrange, B Médecin, M C Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 3, 2004
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer
E Guardiola, F Peyrade, L Chaigneau, et al.
Bulletin Du Cancer
|
November 28, 2008
[Edifice program: analysis of screening exam practices for cancer in France]
J-Y Blay, F Eisinger, O Rixe, et al.
British Journal of Cancer
|
April 17, 1999
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
M C Etienne, X Pivot, J L Formento, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2010
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
F-C Bidard, C Mathiot, A Degeorges, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 2014
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
A Thiery-Vuillemin, G Mouillet, T Nguyen Tan Hon, et al.
British Journal of Cancer
|
February 21, 2013
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D W Miles, S L de Haas, L Y Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
X Pivot, A Awada, D Gedouin, et al.
British Journal of Cancer
|
September 5, 2001
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
X Pivot, E Raymond, B Laguerre, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
Pharmacotherapy
|
December 17, 1997
Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors
J L Lagrange, B Médecin, M C Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 3, 2004
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer
E Guardiola, F Peyrade, L Chaigneau, et al.
Bulletin Du Cancer
|
November 28, 2008
[Edifice program: analysis of screening exam practices for cancer in France]
J-Y Blay, F Eisinger, O Rixe, et al.
British Journal of Cancer
|
April 17, 1999
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
M C Etienne, X Pivot, J L Formento, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2010
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
F-C Bidard, C Mathiot, A Degeorges, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 2014
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
A Thiery-Vuillemin, G Mouillet, T Nguyen Tan Hon, et al.
British Journal of Cancer
|
February 21, 2013
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D W Miles, S L de Haas, L Y Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
X Pivot, A Awada, D Gedouin, et al.
British Journal of Cancer
|
September 5, 2001
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
X Pivot, E Raymond, B Laguerre, et al.
British Journal of Cancer
|
September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard, J-J Voigt, A Laplanche, et al.
Page
of 10